HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a ...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) filed a Form 8-K with the United States Securities and Exchange Commission (SEC). In this filing, Processa Pharmaceuticals disclosed that a copy of a slide ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a ...

Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), currently trading at $0.63 with a market capitalization of just $2.95 million, has been notified by Nasdaq's Listing Qualifications Department that ...

HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), currently trading at $0.63 with a market capitalization of just $2.95 million, has been notified by Nasdaq's Listing Qualifications Department that its ...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), that sends ...

Processa Pharmaceuticals (PCSA) announced the pricing of its “reasonable best efforts” public offering with participation from the Company’s ...